Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Discovering the minimal optimal antipsychotic dose in patients with late-life schizophrenia – an open-label prospective [11C]-Raclopride Positron Emission Tomography study
FY 2014-15
Summary
Schizophrenia (SCZ) is a debilitating illness with prevalence of 1% in global population. Patients with SCZ must receive a lifelong treatment by antipsychotics, which are primary treatments of SCZ, to prevent relapses or re-emergence of symptoms of SCZ. However, longterm high dose of antipsychotics induces several unwanted side effects, such as motor disorders and poor cognitive performance, that are exacerbated with aging. Thus, clinical guidelines recommend the use of lower antipsychotics dose in old patients with schizophrenia. However, there is no empirical data available on age-specific antipsychotic dosing. Therefore, the aim of the current longitudinal study is to establish a clinically effective therapeutic window of antipsychotics with reduced side effects in stable old patients with SCZ.Using a brain imaging technique called Positron Emission Tomography (PET) with a radioactive receptor dye called [11C]-Raclopride, we can measure dopamine D2/3 receptor occupancy (D2/3 R occupancy), which is linked to the tolerability and efficacy of antipsychotics.Using D2/3 R occupancy, we can also estimate the minimal optimal antipsychotic dose.This study will be an open-label prospective clinical PET study to examine relationships between D2/3 R occupancy and therapeutic effects of antipsychotic in clinically stable patients with SCZ aged 55 or older. Our results will provide a novel insight on the optimal dosing of antipsychotics for preventing relapses in old patients with SCZ.Our findings can be translated to determine the lowest effective antipsychotic dose with minimizing the side effects. Reducing side effects will increase patients' adherence rate to antipsychotic treatment, and results in better clinical outcomes.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
331488
Name
Chung Jun Ku
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Discovering the minimal optimal antipsychotic dose in patients with late-life schizophrenia – an open-label prospective [11C]-Raclopride Positron Emission Tomography study
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Antipsychotic Dose Reduction; Antipsychotic-Induced Side Effects; Antipsychotics; Dopamine D2/D3 Receptors; Geriatrics; Late-Life Schizophrenia; Positron Emission Tomography; Relapse Prevention
Abstract
Schizophrenia (SCZ) is a debilitating illness with prevalence of 1% in global population. Patients with SCZ must receive a lifelong treatment by antipsychotics, which are primary treatments of SCZ, to prevent relapses or re-emergence of symptoms of SCZ. However, longterm high dose of antipsychotics induces several unwanted side effects, such as motor disorders and poor cognitive performance, that are exacerbated with aging. Thus, clinical guidelines recommend the use of lower antipsychotics dose in old patients with schizophrenia. However, there is no empirical data available on age-specific antipsychotic dosing. Therefore, the aim of the current longitudinal study is to establish a clinically effective therapeutic window of antipsychotics with reduced side effects in stable old patients with SCZ.Using a brain imaging technique called Positron Emission Tomography (PET) with a radioactive receptor dye called [11C]-Raclopride, we can measure dopamine D2/3 receptor occupancy (D2/3 R occupancy), which is linked to the tolerability and efficacy of antipsychotics.Using D2/3 R occupancy, we can also estimate the minimal optimal antipsychotic dose.This study will be an open-label prospective clinical PET study to examine relationships between D2/3 R occupancy and therapeutic effects of antipsychotic in clinically stable patients with SCZ aged 55 or older. Our results will provide a novel insight on the optimal dosing of antipsychotics for preventing relapses in old patients with SCZ.Our findings can be translated to determine the lowest effective antipsychotic dose with minimizing the side effects. Reducing side effects will increase patients' adherence rate to antipsychotic treatment, and results in better clinical outcomes.
Competitiondate
201412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Chung, Jun Ku
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~